Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/ATelephone
61.2.8415.7300
Address
Homebush 30 Richmond Road Sydney, New South Wales (NSW) 2140
Description
N/A
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.01
Trade Value (12mth)
AU$4,425.00
1 week
0%
1 month
-37.5%
YTD
-50%
1 year
-37.5%
All time high
80.99
EPS 3 yr Growth
5.60%
EBITDA Margin
%
Operating Cashflow
-$3m
Free Cash Flow Return
-39.70%
ROIC
-54.60%
Interest Coverage
-10.80
Quick Ratio
0.30
Shares on Issue (Fully Dilluted)
1562m
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
30 April 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
17 April 25 |
Notification regarding unquoted securities - MEM
×
Notification regarding unquoted securities - MEM |
17 April 25 |
Application for quotation of securities - MEM
×
Application for quotation of securities - MEM |
17 April 25 |
s708A Cleansing Statement
×
s708A Cleansing Statement |
14 April 25 |
$1.275M Placement to Accelerate Commercial Rollout
×
$1.275M Placement to Accelerate Commercial Rollout |
14 April 25 |
Update - Proposed issue of securities - MEM
×
Update - Proposed issue of securities - MEM |
10 April 25 |
Proposed issue of securities - MEM
×
Proposed issue of securities - MEM |
10 April 25 |
Pause in Trading
×
Pause in Trading |
10 April 25 |
Trading Halt
×
Trading Halt |
03 April 25 |
RoXsta offers Effective Oxidative Stress Measurem't 4 Cattle
×
RoXsta offers Effective Oxidative Stress Measurem't 4 Cattle |
24 March 25 |
Felix Trial Confirms Best-in-Class Performance
×
Felix Trial Confirms Best-in-Class Performance |
20 March 25 |
Trading Halt
×
Trading Halt |
13 March 25 |
MEM secures R&D Tax Rebate loan
×
MEM secures R&D Tax Rebate loan |
28 February 25 |
Extension of Convertible Notes
×
Extension of Convertible Notes |
28 February 25 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
25 February 25 |
Investor Presentation Feb 25
×
Investor Presentation Feb 25 |
24 February 25 |
Felix Data lock complete and regulatory submission commenced
×
Felix Data lock complete and regulatory submission commenced |
17 February 25 |
Leading Brazilian Andrology Clinic to test Felix System
×
Leading Brazilian Andrology Clinic to test Felix System |
11 February 25 |
Felix Clinical Trial complete, Data Lock expected in 2 weeks
×
Felix Clinical Trial complete, Data Lock expected in 2 weeks |
23 January 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
16 January 25 |
Publication Highlights Diagnostic Potential of RoXsta TM
×
Publication Highlights Diagnostic Potential of RoXsta TM |
06 January 25 |
Heranova Felix System Utilisation Testing commences in China
×
Heranova Felix System Utilisation Testing commences in China |
23 December 24 |
Top Up Offer Completion
×
Top Up Offer Completion |
20 December 24 |
Bovine Study commences to assess RoXsta antioxidant system
×
Bovine Study commences to assess RoXsta antioxidant system |
20 December 24 |
Application for quotation of securities - MEM
×
Application for quotation of securities - MEM |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.